SKIN The Journal of Cutaneous Medicine

Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Andrew Blauvelt, Neil J. Korman, Joseph F. Merola, Melinda Gooderham, Eugene Balagula, Rebecca Vanlandingham, Michelle Treitel, Keith Wittstock, Kim Hoyt, Subhashis Banerjee, Seemal R. Desai

Page s364

PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Body Surface Area (BSA) Involvement and Baseline Psoriasis Area and Severity Index (PASI)

Jeffrey M. Sobell, Boni Elewski, Subhashis Banerjee, Eugene Balagula, Thomas Scharnitz, Victoria Berger, Kim Hoyt, Paul Yamauchi, Miriam Bettencourt, Michael C. Cameron, Mark Lebwohl

Page s238

PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial

Mark Lebwohl, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Christopher EM Griffiths

Page s239

PDF

Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Diamant Thaçi, Mark Lebwohl, Richard B. Warren, Leon Kircik, Subhashis Banerjee, Andrew Napoli, Renata M. Kisa, Misti Linaberry, Kim Hoyt, Andrew Blauvelt

Page s243

PDF

Deucravacitinib, an Oral Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-controlled Trial (PSORIATYK SCALP)

Kristina Callis Duffin, Christopher E. M. Griffiths, Matthias Hoffmann, Andrew Blauvelt, Eugene Balagula, Andrew Napoli, Ying-Ming Jou, Rachel Dyme, Virginia Hala, Andreas Pinter, Mark Lebwohl

Page s420

PDF

Deucravacitinib Long-Term Efficacy in Week 16 Placebo Crossovers: 3-year Results from the POETYK PSO Program

Mark Lebwohl, Richard B. Warren, Shinichi Imafuku, Jerry Bagel, April W. Armstrong, Thierry Passeron, Subhashis Banerjee, Renata M. Kisa, Eleni Vritzali, Matthew J. Colombo, Thomas Scharnitz, Kim Hoyt, Diamant Thaçi, Andrew Blauvelt

Page s365

PDF

Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-year, Long-term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials

April W. Armstrong, Richard B. Warren, Bruce Strober, Andrew Blauvelt, Yayoi Tada, Thierry Passeron, Diamant Thaçi, Carolin Daamen, Janice Li, Zoran Popmihajlov, John Vaile, Julie Scotto, Mark Lebwohl

Page s532

PDF

Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt

Page s240

PDF

Efficacy of Deucravacitinib over time in Psoriasis by Baseline Total Body Surface Area: Post Hoc Analysis of the Randomized, Double-blind, Placebo-controlled Phase 3b/4 PSORIATYK SCALP Trial

Christopher E.M. Griffiths, Matthias Hoffmann, Andrew Blauvelt, Eugene Balagula, Andrew Napoli, Chun-Yen Cheng, Rachel Dyme, Virginia Hala, Andreas Pinter, Mark Lebwohl

Page s537

PDF

Deucravacitinib in Plaque Psoriasis: Immune Response to and Safety of Pneumococcus and Tetanus Toxoid Vaccines in the POETYK LTE Trial

Joanna Narbutt, Shahram Jacobs, Kim A. Papp, Alessandra Alió, Yi Luo, Yanqiu Shao, Victoria Berger, Carolin Daamen, Kevin Winthrop

Page s534

PDF

Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt

Page s366

PDF

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: evaluation of lipid parameters in the phase 3 POETYK PSO-1 and PSO-2 trials

Mark Lebwohl, Bruce Strober, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, Nehal N. Mehta

Page s115

Poster PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Mark Lebwohl, Bruce Strober, Thomas Scharnitz, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, George Martin

Page s244

PDF

Matching-adjusted indirect comparison (MAIC) of deucravacitinib versus adalimumab for the treatment of patients with moderate to severe plaque psoriasis over 2 years

April W. Armstrong, Sang Hee Park, Vardhaman Patel, Malcolm Hogan, Wei-Jhih Wang, David Davidson, Viktor Chirikov

Page s112

Poster PDF

Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Bruce Strober, Howard Sofen, Shinichi Imafuku, Carle Paul, Melinda Gooderham, Lynda Spelman, Seong Jun Seo, Thierry Passeron, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Matthias Augustin, Linda Stein Gold, Andrew Alexis, Diamant Thaçi, Andrew Blauvelt, Mark Lebwohl

Page s241

PDF

Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Akimichi Morita, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Matthew J. Colombo, John Vaile, Eleni Vritzali, Kim Hoyt, Carolin Daamen, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt

Page s423

PDF

Deucravacitinib in moderate to severe plaque psoriasis: liver transaminase results from the phase 3 POETYK PSO program

Mark Lebwohl, Alexander Egeberg, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, Bruce Strober

Page s116

Poster PDF

Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Akimchi Morita, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Matthew J. Colombo, John Vaile, Eleni Vritzali, Kim Hoyt, Carolin Daamen, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt

Page s406

PDF

Onset of Clinical Response with Deucravacitinib in Patients with Moderate to Severe Scalp Psoriasis: A Post Hoc Analysis of the Phase 3b/4 PSORIATYK SCALP Trial

Matthias Hoffmann, Andrew Blauvelt, Eugene Balagula, Andrew Napoli, Chun-Yen Cheng, Rachel Dyme, Virginia Hala, Stephen Tyring, Jerry Bagel, Mark Lebwohl

Page s539

PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-Reported Outcomes in a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-Controlled Study (PSORIATYK SCALP)

Linda Stein Gold, Michael Sebastian, Eugene Balagula, Brandon Becker, Yichen Zhong, Rachel Dyme, Michael DeRosa, Scott Fretzin, Andreas Pinter, Christopher E. M. Griffiths

Page s533

PDF

Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study

Victoria P. Werth, Marilyn Pike, Joan T. Merrill, Eric Morand, Ronald van Vollenhoven, Coburn Hobar, Nikolay Delev, Vaishali Shah, Brian Sharkey, Thomas Wegman, Ian Catlett, Subhashis Banerjee, Shalabh Singhal

Page s114

Poster PDF

Efficacy of Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Scalp Psoriasis by Baseline Psoriasis Area and Severity Index (PASI) and Baseline Body Surface Area (BSA): A Subanalysis of the Phase 3 Clinical Trial Data

Andrew Blauvelt, Howard Sofen, Jo Lambert, Joseph F. Merola, Mark Lebwohl, Kim Hoyt, Subhashis Banerjee, Thomas Scharnitz, Jeffrey J. Crowley

Page s405

PDF

Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 4 Years in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials

Bruce Strober, Shinichi Imafuku, Carle Paul, Melinda Gooderham, Lynda Spelman, Seong Jun Seo, Thierry Passeron, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Matthias Augustin, Linda Stein Gold, Andrew F. Alexis, Diamant Thaci, Mark Lebwohl, Naiem T. Issa, Michael C. Cameron

Page s407

PDF

Deucravacitinib in Plaque Psoriasis: Laboratory Parameters Through 4 Years of Treatment in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials

Neil J. Korman, Thierry Passeron, Yukari Okubo, Jerry Bagel, Richard B. Warren, Lynda Spelman, Kevin Winthrop, Kim Hoyt, Thomas Scharnitz, Subhashis Banerjee, Diamant Thaçi, Mona Shahriari, Linda Stein Gold

Page s419

PDF

Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial

Alice B. Gottlieb, April W. Armstrong, Joseph F. Merola, Andrew Napoli, Miroslawa Nowak, Subhashis Banerjee, Thomas Lehman, Philip J. Mease

Page s383

PDF

Search

Search Results